BioSpace News Archive

Komen vows to drive breakthroughs for the most-deadly breast cancers and educate those who believe breast cancers are easily treated or always curable

ZyVersa is developing differentiated therapeutic options to meet the significant unmet medical needs of patients with kidney disease through two novel drug development platforms

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut-mediated pathogens, is pleased to announce sales results for its commercially available, over-the-counter gastrointestinal and digestive health supplement Travelan®, for the quarter ended September 30, 2019, of fiscal year 2020 (Q1).

Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of its Helium Plasma Technology, marketed and sold as Renuvion®

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Phase II clinical trial protocol for the treatment of Chronic Kidney Disease (CKD).

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, its President and Chief Executive Officer, will present at two upcoming investor conferences:

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today announced that management will participate in a panel at the H.C. Wainwright 3rd Annual NASH Investor Conference, taking place October 21, 2019 in New York City.

Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced that CEO, Shital Mars will be the keynote speaker at Cold Chain Global Forum in Boston, Massachusetts on October 15-18, 2019.

Fresenius Medical Care North America (FMCNA), the nation’s leading provider of kidney care products and services, released the following statement in response to the signing of AB 290 in California

Bongo® Rx, an FDA cleared medical device for the treatment of mild to moderate obstructive sleep apnea, utilizes no electricity or batteries.